Skip to content

Current ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.4×+0.1×
Eli Lilly logo
Eli LillyLLY
1.5×+0.1×
Bausch Health Companies logo
Bausch Health CompaniesBHC
1.3×0.0×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-0.4×
Prime Medicine logo
Prime MedicinePRME
3.8×-1.0×
Wave Life Sciences logo
Wave Life SciencesWVE
11.3×+8.3×

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M-62.2%
Net income-$3.9M-48.3%
EPS (diluted)-$0.19

Balance sheet

See full
Cash & equivalents$52.5M+32.3%
Total debt$230.4K+2,692%
Total equity$135.4M+153%
Total assets$138.0M+150%

Cash flow

See full
Operating cash flow-$3.5M+38.7%

Valuation

See full
Market cap$587.04M+192%
Enterprise value$534.72M+232%

Returns & leverage

See full
Return on equity-15.9%-6.6pp
Debt / equity0.0×

Where this comes from

Calculated from Monopar Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monopar Therapeutics's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Monopar Therapeutics's current ratio?
Monopar Therapeutics (MNPR) reported current ratio of 56× in Q1 2026.
What is the long-term trend for Monopar Therapeutics's current ratio?
Over 5 years (2020 to 2025), Monopar Therapeutics's current ratio has grown at a 29.2% compound annual growth rate (CAGR), from 14.3× to 51.4×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.